EWP
BIIB icon

Engrave Wealth Partners’s Biogen BIIB Stock Holding History

Engrave Wealth Partners’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-60
Closed -$16K – 93
2020
Q2 		$16K Hold
60
– – 0.01% 200
2020
Q1 		$18K Hold
60
– – 0.02% 159
2019
Q4 		$17K Buy
+60
New +$16.6K 0.02% 240

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Engrave Wealth Partners's BIIB Position: Q3 2020 in Review

Engrave Wealth Partners sold out of Biogen (BIIB) in Q3 2020, closing a stake of 60 shares — an estimated $16K sold.

Engrave Wealth Partners first reported a position in BIIB in Q4 2019 and held it in 3 quarters. The position peaked at $18K in Q1 2020. 1,051 funds tracked by Wall St. Rank hold BIIB as of Q3 2020.

  • Engrave Wealth Partners reported no remaining Biogen position as of Q3 2020 after selling out during the quarter.
  • Engrave Wealth Partners sold 60 Biogen shares in Q3 2020, an estimated $16K.
  • Engrave Wealth Partners first reported a position in Biogen in Q4 2019 and held it in 3 quarters.
  • Engrave Wealth Partners's Biogen position peaked at $18K in Q1 2020.
  • 1,051 funds tracked by Wall St. Rank held Biogen as of Q3 2020.

Based on Engrave Wealth Partners's 13F filing for Q3 2020, filed 8 Oct 2020.